This study MACE as a composite endpoint of all-cause mortality, non-fatal stroke, non – fatal myocardial infarction, unstable angina, and a subset of revascularization after the first event defined in the course of the study, patients received therapy standard of care in addition to high dose Lipitor . ###In 2002, Chugh launched the Oregon sudden unexpected death study, an ambitious population study in 16 hospitals serving a community of about 1 million residents in the Portland metropolitan region.
– Varespladib immediate and selective inhibition of sPLA2 effectively suppressed inflammation following the index event and was detected by a statistically significant reduction in C-reactive protein. ‘We are very excited by these data, ‘Colin Hislop, Senior Vice President of Clinical Anthera Anthera. ‘The positive impact of the treatment of varespladib is consistent with our Phase 3 development plan and provides a robust record to significant clinical benefit for this novel support, first in class therapy. ‘.Self – Clinical Studies of gene therapy on muscular dystrophy Lends insights into the illness.
Is Duchenne is a genetic disease that begin during early childhood, causes progressive muscle wasting, and typically leads to death the age of 20 of respiratory or cardiac muscle failure , the disease, which curve at first. Boy, occurs when a gene in to the X chromosome not make the fundamental muscle proteins the dystrophin present, the best medical therapy simply slow its progression.